1887

Abstract

Mammalian reoviruses exhibit a propensity to replicate in transformed cells. It is currently believed that the interferon-inducible RNA-dependent protein kinase (PKR), an intracellular host-cell resistance factor that is inhibited by an activated -dependent pathway in transformed cells, is responsible for this discrimination. In the present study, reovirus isolates differing in their sensitivity to interferon were obtained by chemical mutagenesis, and examined for their replicative properties in parental and -transformed mouse NIH-3T3 cells. It was observed that most isolates can bypass resistance mechanisms of parental cells at high m.o.i., and that there is a correlation between the ability to discriminate between transformed and parental cells, and interferon sensitivity. Most interestingly, an interferon-hypersensitive mutant virus was more dependent on activation than any other viral isolate. Altogether, this suggests that optimal reovirus isolates could be selected to attack tumour cells depending on the nature of the alterations in interferon-inducible pathways found in these cells.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80628-0
2005-05-01
2024-10-12
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/5/vir861489.html?itemId=/content/journal/jgv/10.1099/vir.0.80628-0&mimeType=html&fmt=ahah

References

  1. Alain T., Hirasawa K., Pon K. J. 9 other authors 2002; Reovirus therapy of lymphoid malignancies. Blood 100:4146–4153 [CrossRef]
    [Google Scholar]
  2. Balachandran S., Barber G. N. 2004; Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5:51–65 [CrossRef]
    [Google Scholar]
  3. Bell J. C., Garson K. A., Lichty B. D., Stojdl D. F. 2002; Oncolytic viruses: programmable tumour hunters. Curr Gene Ther 2:243–254 [CrossRef]
    [Google Scholar]
  4. Bergeron J., Mabrouk T., Garzon S., Lemay G. 1998; Characterization of the thermosensitive ts453 reovirus mutant: increased dsRNA binding of σ 3 protein correlates with interferon resistance. Virology 246:199–210 [CrossRef]
    [Google Scholar]
  5. Chiocca E. A. 2002; Oncolytic viruses. Nat Rev Cancer 2:938–950 [CrossRef]
    [Google Scholar]
  6. Clemens M. J., Elia A. 1997; The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 17:503–524 [CrossRef]
    [Google Scholar]
  7. Coffey M. C., Strong J. E., Forsyth P. A., Lee P. W. 1998; Reovirus therapy of tumors with activated Ras pathway. Science 282:1332–1334 [CrossRef]
    [Google Scholar]
  8. Danis C., Lemay G. 1993; Protein synthesis in different cell lines infected with orthoreovirus serotype 3: inhibition of host-cell protein synthesis correlates with accelerated viral multiplication and cell killing. Biochem Cell Biol 71:81–85 [CrossRef]
    [Google Scholar]
  9. Danis C., Mabrouk T., Faure M., Lemay G. 1997; Interferon has no protective effect during acute or persistent reovirus infection of mouse SC1 fibroblasts. Virus Res 51:139–149 [CrossRef]
    [Google Scholar]
  10. Denzler K. L., Jacobs B. L. 1994; Site-directed mutagenic analysis of reovirus σ 3 protein binding to dsRNA. Virology 204:190–199 [CrossRef]
    [Google Scholar]
  11. Duncan M. R., Stanish S. M., Cox D. C. 1978; Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 28:444–449
    [Google Scholar]
  12. Etoh T., Himeno Y., Matsumoto T., Aramaki M., Kawano K., Nishizono A., Kitano S. 2003; Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res 9:1218–1223
    [Google Scholar]
  13. Fields B. N., Joklik W. K. 1969; Isolation and preliminary genetic and biochemical characterization of temperature-sensitive mutants of reovirus. Virology 37:335–342 [CrossRef]
    [Google Scholar]
  14. Gale M. Jr, Katze M. G. 1998; Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol Ther 78:29–46 [CrossRef]
    [Google Scholar]
  15. Gupta S. L., Holmes S. L., Mehra L. L. 1982; Interferon action against reovirus: activation of interferon-induced protein kinase in mouse L929 cells upon reovirus infection. Virology 120:495–499 [CrossRef]
    [Google Scholar]
  16. Hashiro G., Loh P. C., Yau J. T. 1977; The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 54:307–315 [CrossRef]
    [Google Scholar]
  17. Hirasawa K., Nishikawa S. G., Norman K. L., Alain T., Kossakowska A., Lee P. W. 2002; Oncolytic reovirus against ovarian and colon cancer. Cancer Res 62:1696–1701
    [Google Scholar]
  18. Hirasawa K., Nishikawa S. G., Norman K. L., Coffey M. C., Thompson B. G., Yoon C. S., Waisman D. M., Lee P. W. 2003; Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63:348–353
    [Google Scholar]
  19. Huismans H., Joklik W. K. 1976; Reovirus-coded polypeptides in infected cells: isolation of two native monomeric polypeptides with affinity for single-stranded and double-stranded RNA, respectively. Virology 70:411–424 [CrossRef]
    [Google Scholar]
  20. Ikegami N., Gomatos P. J. 1968; Temperature-sensitive conditional-lethal mutants of reovirus 3. I. Isolation and characterization. Virology 36:447–458 [CrossRef]
    [Google Scholar]
  21. Imani F., Jacobs B. L. 1988; Inhibitory activity for the interferon-induced protein kinase is associated with the reovirus serotype 1 σ 3 protein. Proc Natl Acad Sci U S A 85:7887–7891 [CrossRef]
    [Google Scholar]
  22. Jacobs B. L., Ferguson R. E. 1991; The Lang strain of reovirus serotype 1 and the Dearing strain of reovirus serotype 3 differ in their sensitivities to beta interferon. J Virol 65:5102–5104
    [Google Scholar]
  23. Jacobs B. L., Langland J. O. 1998; Reovirus sigma 3 protein: dsRNA binding and inhibition of RNA-activated protein kinase. Curr Top Microbiol Immunol 233:185–196
    [Google Scholar]
  24. Katze M. G. 1993; Games viruses play: a strategic initiative against the interferon-induced dsRNA-activated 68,000 Mr protein kinase. Semin Virol 4:259–268 [CrossRef]
    [Google Scholar]
  25. Katze M. G. 1995; Regulation of the interferon-induced PKR: can viruses cope?. Trends Microbiol 3:75–78 [CrossRef]
    [Google Scholar]
  26. Kilani R. T., Tamimi Y., Hanel E. G., Wong K. K., Karmali S., Lee P. W., Moore R. B. 2003; Selective reovirus killing of bladder cancer in a co-culture spheroid model. Virus Res 93:1–12 [CrossRef]
    [Google Scholar]
  27. Koleske A. J., Baltimore D., Lisanti M. P. 1995; Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci U S A 92:1381–1385 [CrossRef]
    [Google Scholar]
  28. Liemann S., Chandran K., Baker T. S., Nibert M. L., Harrison S. C. 2002; Structure of the reovirus membrane-penetration protein, μ 1, in a complex with its protector protein, σ 3. Cell 108:283–295 [CrossRef]
    [Google Scholar]
  29. Lloyd R. M., Shatkin A. J. 1992; Translational stimulation by reovirus polypeptide σ 3: substitution for VAI RNA and inhibition of phosphorylation of the α subunit of eukaryotic initiation factor 2. J Virol 66:6878–6884
    [Google Scholar]
  30. Mabrouk T., Danis C., Lemay G. 1995; Two basic motifs of reovirus sigma 3 protein are involved in double-stranded RNA binding. Biochem Cell Biol 73:137–145 [CrossRef]
    [Google Scholar]
  31. Miller F. E., Samuel C. E. 1992; Proteolytic cleavage of the reovirus sigma 3 protein results in enhanced double-stranded RNA-binding activity: identification of a repeated basic amino acid motif within the C-terminal binding region. J Virol 66:5347–5356
    [Google Scholar]
  32. Miyamoto N. G., Samuel C. E. 1980; Mechanism of interferon action. Interferon-mediated inhibition of reovirus mRNA translation in the absence of detectable mRNA degradation but in the presence of protein phosphorylation. Virology 107:461–475 [CrossRef]
    [Google Scholar]
  33. Mullen J. T., Tanabe K. K. 2002; Viral oncolysis. Oncologist 7:106–119 [CrossRef]
    [Google Scholar]
  34. Mundschau L. J., Faller D. V. 1992; Oncogenic Ras induces an inhibitor of double-stranded RNA-dependent eukaryotic initiation factor 2 α -kinase activation. J Biol Chem 267:23092–23098
    [Google Scholar]
  35. Mundschau L. J., Faller D. V. 1994; Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells. Biochimie 76:792–800 [CrossRef]
    [Google Scholar]
  36. Nilsen T. W., Maroney P. A., Baglioni C. 1982; Inhibition of protein synthesis in reovirus-infected HeLa cells with elevated levels of interferon-induced protein kinase activity. J Biol Chem 257:14593–14596
    [Google Scholar]
  37. Norman K. L., Lee P. W. 2000; Reovirus as a novel oncolytic agent. J Clin Invest 105:1035–1038 [CrossRef]
    [Google Scholar]
  38. Norman K. L., Coffey M. C., Hirasawa K., Demetrick D. J., Nishikawa S. G., DiFrancesco L. M., Strong J. E., Lee P. W. 2002; Reovirus oncolysis of human breast cancer. Hum Gene Ther 13:641–652 [CrossRef]
    [Google Scholar]
  39. Norman K. L., Hirasawa K., Yang A.-D., Shields M. A., Lee P. W. K. 2004; Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A 101:11099–11104 [CrossRef]
    [Google Scholar]
  40. Olland A. M., Jane-Valbuena J., Schiff L. A., Nibert M. L., Harrison S. C. 2001; Structure of the reovirus outer capsid and dsRNA-binding protein σ 3 at 1·8 Å resolution. EMBO J 20:979–989 [CrossRef]
    [Google Scholar]
  41. Patrick M., Duncan R., Coombs K. M. 2001; Generation and genetic characterization of avian reovirus temperature-sensitive mutants. Virology 284:113–122 [CrossRef]
    [Google Scholar]
  42. Proud C. G. 1992; Protein phosphorylation in translational control. Curr Top Cell Regul 32:243–369
    [Google Scholar]
  43. Samuel C. E. 1998; Reoviruses and the interferon system. Curr Top Microbiol Immunol 233:125–145
    [Google Scholar]
  44. Samuel C. E., Kuhen K. L., George C. X., Ortega L. G., Rende-Fournier R., Tanaka H. 1997; The PKR protein kinase – an interferon-inducible regulator of cell growth and differentiation. Int J Hematol 65:227–237 [CrossRef]
    [Google Scholar]
  45. Schiff L. A. 1998; Reovirus capsid proteins sigma 3 and mu 1: interactions that influence viral entry, assembly, and translational control. Curr Top Microbiol Immunol 233:167–183
    [Google Scholar]
  46. Schmechel S., Chute M., Skinner P., Anderson R., Schiff L. 1997; Preferential translation of reovirus mRNA by a σ 3-dependent mechanism. Virology 232:62–73 [CrossRef]
    [Google Scholar]
  47. Sherry B., Torres J., Blum M. A. 1998; Reovirus induction of and sensitivity to beta interferon in cardiac myocyte cultures correlate with induction of myocarditis and are determined by viral core proteins. J Virol 72:1314–1323
    [Google Scholar]
  48. Strong J. E., Lee P. W. 1996; The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 70:612–616
    [Google Scholar]
  49. Strong J. E., Coffey M. C., Tang D., Sabinin P., Lee P. W. 1998; The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17:3351–3362 [CrossRef]
    [Google Scholar]
  50. Thirukkumaran C. M., Luider J. M., Stewart D. A., Cheng T., Lupichuk S. M., Nodwell M. J., Russell J. A., Auer I. A., Morris D. G. 2003; Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 102:377–387 [CrossRef]
    [Google Scholar]
  51. Virgin H. W. I., Tyler K. L., Dermody T. S. 1996; Reovirus. In Viral Pathogenesis Edited by Nathanson N. Philadelphia: Lippincott-Raven Press;
    [Google Scholar]
  52. Wang Q., Bergeron J., Mabrouk T., Lemay G. 1996; Site-directed mutagenesis of the double-stranded RNA binding domain of bacterially-expressed σ 3 reovirus protein. Virus Res 41:141–151 [CrossRef]
    [Google Scholar]
  53. Wiebe M. E., Joklik T. W. 1975; The mechanism of inhibition of reovirus replication by interferon. Virology 66:229–240 [CrossRef]
    [Google Scholar]
  54. Wilcox M. E., Yang W., Senger D. 8 other authors 2001; Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 93:903–912 [CrossRef]
    [Google Scholar]
  55. Wildner O. 2001; Oncolytic viruses as therapeutic agents. Ann Med 33:291–304 [CrossRef]
    [Google Scholar]
  56. Yang W. Q., Senger D., Muzik H. 11 other authors 2003; Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer Res 63:3162–3172
    [Google Scholar]
  57. Yue Z., Shatkin A. J. 1997; Double-stranded RNA-dependent protein kinase (PKR) is regulated by reovirus structural proteins. Virology 234:364–371 [CrossRef]
    [Google Scholar]
/content/journal/jgv/10.1099/vir.0.80628-0
Loading
/content/journal/jgv/10.1099/vir.0.80628-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error